Global Urothelial Carcinoma Treatment Market Statistics, Development and Growth 2017 to 2023
Summary – A New Market Study, “Urothelial
Carcinoma Treatment Market, 2012 to 2023” Has Been Featured On Wiseguyreports.
Market Outline: Urothelial Carcinoma
Treatment Market
Urothelial
carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma
is a type of cancer that occurs in the urinary system and it is most common
type of bladder cancer of the ureter, urachus and urethra. Urothelial cell
carcinoma starts from transitional epithelium. Potential signs in recognising
the urothelial carcinoma include blood in urine, persistent back pain and
painful urination. Generally, urothelial cell carcinoma is diagnosed using the
blood tests and scanning. Treatment may include anticancer drugs,
antibacterials to reduce or stop the growth of cancer cells and other
treatments such as radiotherapy or nephroureterectomy are indicated.
Market
Dynamics: Urothelial Carcinoma Treatment Market
Urothelial
carcinoma treatment market is driven by the increase in global prevalence of
the bladder cancer and emergence of potential diagnostics for identifying
bladder cancer. Furthermore, increase funding for R&D activities to develop
new cancer therapies and growing awareness regarding early diagnosis of cancer
as a result of awareness programs or other initiatives by government and
non-government organizations are expected to boost the urothelial carcinoma
treatment market over the forecast period. However, high cost of R&D for
development of new drugs and presence of generic drugs in the market are
expected to hamper the market revenue growth during the forecast period.
Market Scope:
Urothelial Carcinoma Treatment Market
Global
urothelial carcinoma treatment market is segmented based on type of treatment,
and distribution channel
Based on
treatment, it segmented into
Immunotherapy
Radiotherapy
Chemotherapy
Others
Based on
distribution channel, it is segmented into
Hospital
Pharmacies
Retail
Pharmacies
Others
Market
Summary: Urothelial Carcinoma Treatment Market
Global
urothelial carcinoma treatment market growth is driven by increase in global
prevalence rate of bladder cancer. According to World Cancer Research Fund
International, bladder cancer is the ninth most common cancer in the world and
in the year 2012 - 430,000 new cases were diagnosed. The market has many large
players and actively developing and launching of new products related to
urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic
A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and
CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline
drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical
trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in
phase 1 clinical trials) are expected to boost future revenue forecasts.
Region
Analysis: Urothelial Carcinoma Treatment Market
Geographically,
urothelial carcinoma treatment market has been segmented into Latin America,
Europe, Asia- Pacific, North America, and the Middle East & Africa. North
America expected to grow at significant rates owing to growing prevalence of
bladder cancer, increase in awareness and well-established healthcare
infrastructure. American Cancer Society estimates that, about 79,030 new cases
of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at
notable rates owing to the factors such as growing awareness related to early
diagnosis of cancer and developed healthcare infrastructure coupled with
prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit
significant growth opportunity owing to developing healthcare infrastructure
and low R&D costs.
Market
Participants: Urothelial Carcinoma Treatment Market
Some of the
players in Market are GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.),
Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany), Eisai Co.
(Japan), Sanofi S.A. (France), and Bristol-Myers Squibb (U.S.) to name a few
Notable
Market Developments: Urothelial carcinoma Treatment Market
In May 2017,
U.S. Food and Drug Administration approved Sereno Inc.’s (E. Merck KG) BAVENCIO
(avelumab) for the treatment of urothelial carcinoma.
In February
2017, U.S. FDA has approved Bristol-Mayer Squibb Company’s OPDIVO (Nivolumab) for
the treatment of urothelial carcinoma.
For More Details : https://www.wiseguyreports.com/reports/2753937-urothelial-carcinoma-treatment-market-2012-to-2023
About Us:
Wise Guy Reports Is Part Of The Wise Guy Research Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe.
Contact Us:
Norah
Trent
Ph: +162-825-80070 (Us)
Ph: +44 2035002763 (Uk)
Comments
Post a Comment